In partnership with Guideline Central, Endocrine Society has developed an educational package to improve knowledge and competencies for assessment, management, and treatment, especially with new therapies, for postmenopausal osteoporosis, and how to optimally use these guidelines in clinical practice.

This guideline toolkit aims to provide: 

• Increased knowledge to endocrinologists and allied providers managing patients with postmenopausal osteoporosis, in an engaging manner.
• Knowledge to clinicians who do not treat high-risk patients on a regular basis but will nonetheless benefit from insights gained because of this digital toolkit on emerging therapies.

Additionally, these guidelines take steps towards improving outcomes for patients who suffer from postmenopausal osteoporosis. 

Test your knowledge about newest guideline recommendations, current evidence, and strategies to individualize treatment for patients with T2D using GLP-1 RAs by building your own case studies. This will help your patients achieve A_1C targets, particularly those with comorbidities including obesity, cardiovascular disease, NAFLD/NASH, transplants, PCOS and more!  Additionally, this will help you identify various social determinants of health (SDoH) that may be unrecognizable and help you direct your patients in changing important modifiable behaviors (like sleep, stress, smoking cessation, and alcohol use).

Expires October 27, 2023

What role might novel agents play, and how can endocrinologists engage with their patients to make better therapeutic choices? During the session, previously hosted at the 58th EASD Annual Meeting, experts will explain the incretin effect and the roles of GLP-1 and GIP, as well as the potential benefits of agonism of multiple receptors that affect energy homeostasis; they will also interpret the clinical implications of new and emerging data for the first-in-class dual GLP-1 and GIP agonist. Case studies will identify individuals with T2D who may benefit from earlier treatment intensification to improve overall health and delineate practical considerations to help individuals with T2D achieve optimal outcomes.

Expires October 29, 2023